GEN Exclusives

More »

GEN News Highlights

More »
Dec 10, 2010

Fatal Liver Injury Prompts Pfizer to Pull Thelin from the Market

Fatal Liver Injury Prompts Pfizer to Pull Thelin from the Market

Firm is also stopping clinical trials with this PAH medication.[olly-Fotolia.com]

  • Pfizer is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) from Australia, Canada, and the EU, where they are approved. In addition, the firm is discontinuing worldwide clinical studies of this endothelin A receptor antagonist.

    The decision was based on a review of emerging safety information from clinical trials and post-marketing reports. While liver toxicity is a known complication of the class of drugs to which Thelin belongs, a new potentially life-threatening idiosyncratic risk of liver injury with Thelin has been observed.

    Given the availability of alternate treatments, Pfizer noted that the overall benefit of Thelin no longer outweighs the risk in the general PAH patient population. Pfizer recommends that no new patients be prescribed Thelin and that patients receiving the drug be transitioned to appropriate alternate therapies as soon as safely possible.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?